Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome

S D Rosenzweig; J Yancoski; A Bernasconi; S Krasovec; B E Marciano; L Casimir; G Berberian; N Símboli; M Rousseau; G Calle

doi:10.1016/j.jinf.2005.07.009

Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome

J Infect. 2006 Mar;52(3):e69-72. doi: 10.1016/j.jinf.2005.07.009. Epub 2005 Sep 19.

Authors

S D Rosenzweig¹, J Yancoski, A Bernasconi, S Krasovec, B E Marciano, L Casimir, G Berberian, N Símboli, M Rousseau, G Calle

Affiliation

¹ Servicio de Inmunología, Hospital Nacional de Pediatría J.P. Garrahan, Buenos Aires, Argentina. [email protected]

PMID: 16181679
DOI: 10.1016/j.jinf.2005.07.009

Abstract

Patients with mutations in the IFNgamma/IL-12 pathway show an exquisite susceptibility to mycobacterial diseases. An IL-12Rbeta1 deficient patient with impaired intestinal absorption suffered from a 13 year culture-positive Mycobacterium bovis-BCG infection with acquired multidrug resistance. A combined parenteral and enteral anti-mycobacterial treatment, including recombinant IFNgamma, helped to clear his infection.

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Antitubercular Agents / adverse effects
Antitubercular Agents / therapeutic use*
Genetic Predisposition to Disease
Humans
Male
Mycobacterium bovis / isolation & purification*
Receptors, Interleukin-12 / deficiency*
Receptors, Interleukin-12 / genetics
Tuberculosis / drug therapy*
Tuberculosis / genetics*
Tuberculosis / microbiology

Substances

Antitubercular Agents
IL12RB1 protein, human
Receptors, Interleukin-12

Grants and funding

R01TW006644/TW/FIC NIH HHS/United States